| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Ewing | 6 | 2020 | 406 | 1.630 |
Why?
|
| Exercise Therapy | 9 | 2023 | 288 | 1.590 |
Why?
|
| Exercise | 10 | 2023 | 1183 | 1.590 |
Why?
|
| Physical Conditioning, Animal | 3 | 2019 | 112 | 1.410 |
Why?
|
| Doxorubicin | 5 | 2020 | 3005 | 1.360 |
Why?
|
| Bone Neoplasms | 7 | 2020 | 2576 | 1.270 |
Why?
|
| Vascular Remodeling | 2 | 2019 | 48 | 1.260 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 3 | 2023 | 84 | 1.140 |
Why?
|
| Capillary Permeability | 2 | 2020 | 114 | 0.840 |
Why?
|
| Osteosarcoma | 2 | 2020 | 929 | 0.780 |
Why?
|
| Pancreatic Neoplasms | 10 | 2023 | 5061 | 0.710 |
Why?
|
| Oxadiazoles | 1 | 2020 | 57 | 0.710 |
Why?
|
| Thiophenes | 1 | 2020 | 148 | 0.670 |
Why?
|
| Melanoma, Experimental | 3 | 2016 | 368 | 0.620 |
Why?
|
| Thrombospondin 1 | 2 | 2016 | 55 | 0.610 |
Why?
|
| Diet Therapy | 1 | 2017 | 52 | 0.600 |
Why?
|
| Endothelium, Vascular | 3 | 2016 | 891 | 0.560 |
Why?
|
| Quality of Life | 6 | 2023 | 4532 | 0.540 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2022 | 1724 | 0.510 |
Why?
|
| Osteogenesis | 1 | 2016 | 271 | 0.500 |
Why?
|
| Neovascularization, Pathologic | 4 | 2021 | 1547 | 0.480 |
Why?
|
| NFATC Transcription Factors | 4 | 2016 | 96 | 0.480 |
Why?
|
| Neoplasms, Experimental | 2 | 2018 | 750 | 0.470 |
Why?
|
| Pyridines | 1 | 2020 | 1244 | 0.440 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 622 | 0.440 |
Why?
|
| Pediatric Obesity | 1 | 2017 | 364 | 0.430 |
Why?
|
| Pericytes | 2 | 2010 | 96 | 0.420 |
Why?
|
| Pyrazoles | 1 | 2020 | 1471 | 0.390 |
Why?
|
| Mice | 20 | 2023 | 34495 | 0.390 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 3821 | 0.380 |
Why?
|
| Endothelial Cells | 5 | 2020 | 1048 | 0.370 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2020 | 726 | 0.360 |
Why?
|
| Calcineurin | 3 | 2016 | 128 | 0.350 |
Why?
|
| Animals | 22 | 2023 | 59536 | 0.340 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2010 | 330 | 0.310 |
Why?
|
| Mice, Nude | 5 | 2020 | 4307 | 0.290 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 650 | 0.280 |
Why?
|
| Melanoma | 1 | 2023 | 5317 | 0.280 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 943 | 0.270 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 1763 | 0.240 |
Why?
|
| Neoplasms | 5 | 2023 | 15193 | 0.220 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2022 | 20 | 0.220 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2022 | 84 | 0.210 |
Why?
|
| Cell Line, Tumor | 6 | 2022 | 14551 | 0.200 |
Why?
|
| Preoperative Care | 2 | 2018 | 1529 | 0.200 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2023 | 160 | 0.200 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 10 | 0.200 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 14289 | 0.200 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2021 | 36 | 0.200 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 3869 | 0.190 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 102 | 0.190 |
Why?
|
| Humans | 33 | 2023 | 261506 | 0.190 |
Why?
|
| Walking | 2 | 2019 | 277 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 6 | 2018 | 6942 | 0.180 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 324 | 0.180 |
Why?
|
| Medical Oncology | 2 | 2019 | 1423 | 0.180 |
Why?
|
| Mice, Transgenic | 5 | 2021 | 4143 | 0.180 |
Why?
|
| Phosphorylation | 3 | 2023 | 4804 | 0.180 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 77 | 0.170 |
Why?
|
| Pediatrics | 2 | 2019 | 1141 | 0.170 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 2864 | 0.170 |
Why?
|
| Endoglin | 1 | 2018 | 43 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1586 | 0.170 |
Why?
|
| Frailty | 1 | 2021 | 113 | 0.170 |
Why?
|
| Arteries | 1 | 2020 | 274 | 0.170 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 7222 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 122 | 0.160 |
Why?
|
| Anthracyclines | 1 | 2020 | 331 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 2020 | 246 | 0.160 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2016 | 30 | 0.150 |
Why?
|
| Sp7 Transcription Factor | 1 | 2016 | 27 | 0.150 |
Why?
|
| Cardiotoxicity | 1 | 2018 | 155 | 0.150 |
Why?
|
| Shear Strength | 1 | 2016 | 35 | 0.150 |
Why?
|
| Home Care Services | 1 | 2017 | 92 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2019 | 667 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 560 | 0.140 |
Why?
|
| Body Composition | 1 | 2019 | 595 | 0.140 |
Why?
|
| Phenotype | 3 | 2023 | 6295 | 0.140 |
Why?
|
| Cerebellar Neoplasms | 1 | 2021 | 434 | 0.140 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2016 | 45 | 0.140 |
Why?
|
| Cancer Survivors | 2 | 2021 | 650 | 0.140 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 88 | 0.140 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2016 | 98 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 598 | 0.130 |
Why?
|
| Medulloblastoma | 1 | 2021 | 540 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2018 | 279 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2019 | 703 | 0.130 |
Why?
|
| HEK293 Cells | 2 | 2016 | 1489 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2023 | 935 | 0.130 |
Why?
|
| Mice, SCID | 2 | 2021 | 1869 | 0.120 |
Why?
|
| Testis | 1 | 2018 | 717 | 0.120 |
Why?
|
| Calcium-Binding Proteins | 3 | 2013 | 545 | 0.120 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 1082 | 0.120 |
Why?
|
| Immunologic Surveillance | 1 | 2014 | 60 | 0.120 |
Why?
|
| Survivors | 1 | 2020 | 1031 | 0.120 |
Why?
|
| Deoxycytidine | 1 | 2019 | 1353 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2020 | 32848 | 0.120 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2013 | 53 | 0.110 |
Why?
|
| Thrombopoiesis | 1 | 2013 | 16 | 0.110 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2013 | 10 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 1519 | 0.110 |
Why?
|
| Weight Loss | 1 | 2017 | 627 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 1011 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 1299 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1664 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 1249 | 0.110 |
Why?
|
| Megakaryocytes | 1 | 2013 | 104 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 2314 | 0.110 |
Why?
|
| Aging | 1 | 2021 | 1582 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2292 | 0.100 |
Why?
|
| Heart | 1 | 2018 | 1223 | 0.100 |
Why?
|
| Cell Line | 3 | 2018 | 5114 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 598 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2022 | 3341 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 755 | 0.090 |
Why?
|
| Physical Fitness | 2 | 2022 | 122 | 0.090 |
Why?
|
| Prognosis | 2 | 2017 | 21713 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 1688 | 0.080 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 764 | 0.080 |
Why?
|
| Receptor, Notch1 | 1 | 2010 | 218 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 1533 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 732 | 0.080 |
Why?
|
| Male | 10 | 2022 | 123000 | 0.080 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2021 | 164 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 8865 | 0.080 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1026 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3230 | 0.080 |
Why?
|
| Signal Transduction | 5 | 2016 | 11965 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2016 | 5710 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 6550 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 5767 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 1581 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2010 | 2074 | 0.060 |
Why?
|
| Self Report | 2 | 2019 | 756 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2021 | 5637 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 1439 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2016 | 5270 | 0.050 |
Why?
|
| Lung | 1 | 2013 | 3151 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 1242 | 0.050 |
Why?
|
| Ribose | 1 | 2021 | 32 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2010 | 4078 | 0.050 |
Why?
|
| Sirtuin 1 | 1 | 2022 | 89 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2021 | 113 | 0.050 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 9 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 249 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2022 | 185 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2021 | 7226 | 0.050 |
Why?
|
| Feedback | 1 | 2021 | 198 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 170 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 5377 | 0.050 |
Why?
|
| Polydeoxyribonucleotides | 1 | 2019 | 7 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2021 | 211 | 0.050 |
Why?
|
| Cholagogues and Choleretics | 1 | 2019 | 33 | 0.050 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 51 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2022 | 382 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 4320 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2014 | 1070 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2019 | 12873 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2022 | 411 | 0.040 |
Why?
|
| Muscle Proteins | 2 | 2013 | 549 | 0.040 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2018 | 18 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 664 | 0.040 |
Why?
|
| Hand Strength | 1 | 2019 | 65 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 827 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2019 | 231 | 0.040 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2018 | 47 | 0.040 |
Why?
|
| Bilirubin | 1 | 2019 | 221 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 905 | 0.040 |
Why?
|
| Stem Cell Niche | 1 | 2018 | 94 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 110 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 4654 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 10331 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 2 | 2023 | 4975 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 1265 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2019 | 337 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 324 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 649 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 503 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 348 | 0.040 |
Why?
|
| Prostate | 1 | 2022 | 1088 | 0.040 |
Why?
|
| Fertility Preservation | 1 | 2018 | 150 | 0.040 |
Why?
|
| Spermatogenesis | 1 | 2018 | 308 | 0.040 |
Why?
|
| Germ Cells | 1 | 2018 | 335 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 499 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 333 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 603 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1945 | 0.030 |
Why?
|
| Child | 3 | 2021 | 29154 | 0.030 |
Why?
|
| Mitochondria | 1 | 2021 | 1282 | 0.030 |
Why?
|
| COS Cells | 1 | 2014 | 377 | 0.030 |
Why?
|
| Cell Movement | 2 | 2014 | 2466 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 1052 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 1270 | 0.030 |
Why?
|
| Receptor, TIE-2 | 1 | 2013 | 82 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2014 | 177 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 2522 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 626 | 0.030 |
Why?
|
| Aged | 4 | 2019 | 70117 | 0.030 |
Why?
|
| Endothelium | 1 | 2013 | 158 | 0.030 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 150 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 269 | 0.030 |
Why?
|
| Platelet Count | 1 | 2013 | 490 | 0.030 |
Why?
|
| Apoptosis | 2 | 2018 | 7591 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2014 | 577 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 21445 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 1154 | 0.020 |
Why?
|
| Female | 5 | 2019 | 141928 | 0.020 |
Why?
|
| Fibrosis | 1 | 2014 | 793 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 11538 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2803 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 1946 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4314 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 4938 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 603 | 0.020 |
Why?
|
| Gene Expression | 1 | 2018 | 3570 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2013 | 226 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 31252 | 0.020 |
Why?
|
| Homeostasis | 1 | 2014 | 950 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 2884 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 8873 | 0.020 |
Why?
|
| Ataxins | 1 | 2008 | 91 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1987 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 3472 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 2508 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 5047 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2008 | 114 | 0.020 |
Why?
|
| Ataxin-1 | 1 | 2008 | 148 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2014 | 1682 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1546 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5687 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 1399 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 2084 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 272 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2054 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 1498 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 1823 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 2265 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 77950 | 0.010 |
Why?
|
| United States | 1 | 2021 | 15433 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 17523 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 1491 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 12926 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 7789 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 3343 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 86204 | 0.010 |
Why?
|